Impact of Media Coverage on Influenza Vaccine Coverage in Elderly Individuals from 2020 to 2021 in the Republic of Korea
Increased awareness of adverse events following immunization (AEFI) can disrupt vaccination programs. In South Korea, a report of alleged influenza vaccine-related deaths attracted significant media attention in 2020. We retrieved the vaccination coverage and AEFI data to determine their association with media coverage. Between 2015 and 2019, the vaccination coverage rate ranged between 80.5% and 83.3%; however, the vaccination coverage rate declined significantly from 2020 to 2021 to 73.6% (p < 0.0001). During the 43rd week of 2020, following a large amount of media coverage on vaccine safety issues, the number of cases with AEFI reached 60. Between 2015 and 2020, the mortality rate ratios for influenza vaccines and non-vaccines ranged between 0.1296 (95% confidence interval (CI), 0.1262-0.1331, p < 0.0001) and 0.1608 (95% CI, 0.1572-0.1644, p < 0.0001). Vaccine safety surveillance should be continued in conjunction with investigation and transparent risk communication to maintain public trust in vaccines and vaccinations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Vaccines - 9(2021), 4 vom: 10. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kwon, Yunhyung [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Death |
|---|
| Anmerkungen: |
Date Revised 02.05.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines9040367 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32473364X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32473364X | ||
| 003 | DE-627 | ||
| 005 | 20231225190939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines9040367 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1082.xml |
| 035 | |a (DE-627)NLM32473364X | ||
| 035 | |a (NLM)33920117 | ||
| 035 | |a (PII)367 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kwon, Yunhyung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Media Coverage on Influenza Vaccine Coverage in Elderly Individuals from 2020 to 2021 in the Republic of Korea |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.05.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Increased awareness of adverse events following immunization (AEFI) can disrupt vaccination programs. In South Korea, a report of alleged influenza vaccine-related deaths attracted significant media attention in 2020. We retrieved the vaccination coverage and AEFI data to determine their association with media coverage. Between 2015 and 2019, the vaccination coverage rate ranged between 80.5% and 83.3%; however, the vaccination coverage rate declined significantly from 2020 to 2021 to 73.6% (p < 0.0001). During the 43rd week of 2020, following a large amount of media coverage on vaccine safety issues, the number of cases with AEFI reached 60. Between 2015 and 2020, the mortality rate ratios for influenza vaccines and non-vaccines ranged between 0.1296 (95% confidence interval (CI), 0.1262-0.1331, p < 0.0001) and 0.1608 (95% CI, 0.1572-0.1644, p < 0.0001). Vaccine safety surveillance should be continued in conjunction with investigation and transparent risk communication to maintain public trust in vaccines and vaccinations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a death | |
| 650 | 4 | |a influenza | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a vaccine | |
| 700 | 1 | |a Choe, Young June |e verfasserin |4 aut | |
| 700 | 1 | |a Yun, Jae-Won |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hee Kyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sungnam |e verfasserin |4 aut | |
| 700 | 1 | |a Chun, Chaemin |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Yeon Haw |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, HeeJung |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Hyun-Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yeonkyoeng |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jae Young |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Seon Kui |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Young-Joon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 9(2021), 4 vom: 10. Apr. |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:4 |g day:10 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines9040367 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 4 |b 10 |c 04 | ||